CryoPort (NASDAQ:CYRX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

CryoPort (NASDAQ:CYRX) posted its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), Zacks reports. CryoPort had a negative return on equity of 7.13% and a negative net margin of 20.05%.The business had revenue of $48.97 million for the quarter, compared to analyst estimates of $48.18 million.

Here are the key takeaways from CryoPort’s conference call:

• Revenue reached $49 million in the second quarter, with Life Sciences Services revenue up 15% year over year, commercial cell and gene therapy support revenue up 9%, and clinical-trial support revenue up 12%.
• Cryoport achieved positive adjusted EBITDA of $400,000, a $1.3 million year-over-year improvement, and generated approximately $5 million of operating cash flow in the first half, supporting management’s path toward sustainable profitability.
• The company’s pipeline remains broad, with 779 clinical trials supported globally, 22 commercial cell and gene therapies, and expectations for 11 potential BLA/MAA filings, five new therapy approvals, and one label or geographic expansion during the remainder of 2026.
• Cryoport reaffirmed its 2026 continuing-operations revenue guidance of $192 million to $196 million rather than raising it, citing geopolitical and macroeconomic uncertainty despite strong underlying demand.
• New growth initiatives—including IntegriCell cryopreservation services, the Fusion 811 freezer, China-based manufacturing, and new supply-chain facilities in Paris and Santa Ana—are expected to expand future capacity, although IntegriCell is not expected to contribute significantly to 2026 revenue.

CryoPort Price Performance

Shares of NASDAQ CYRX traded up $0.41 during trading hours on Friday, reaching $15.12. 1,069,240 shares of the stock were exchanged, compared to its average volume of 609,580. The stock’s fifty day simple moving average is $15.50 and its 200 day simple moving average is $11.89. CryoPort has a 52 week low of $7.51 and a 52 week high of $16.89.

Insider Activity at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 169,427 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at $1,787,259.50. This represents a 60.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Edward J. Zecchini sold 33,600 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the transaction, the insider directly owned 109,719 shares in the company, valued at approximately $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 227,641 shares of company stock worth $3,622,515 in the last ninety days. 9.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On CryoPort

Institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC bought a new position in CryoPort during the fourth quarter worth about $113,000. Invesco Ltd. boosted its holdings in CryoPort by 19.3% in the 4th quarter. Invesco Ltd. now owns 96,541 shares of the company’s stock valued at $927,000 after purchasing an additional 15,607 shares during the period. XTX Topco Ltd acquired a new position in shares of CryoPort during the 4th quarter worth approximately $424,000. Tudor Investment Corp ET AL grew its position in shares of CryoPort by 3.3% during the 4th quarter. Tudor Investment Corp ET AL now owns 300,414 shares of the company’s stock worth $2,884,000 after purchasing an additional 9,690 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of CryoPort during the 4th quarter worth approximately $97,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CYRX shares. Roth Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of CryoPort in a report on Friday. BTIG Research upped their price objective on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, July 24th. Needham & Company LLC increased their price objective on shares of CryoPort from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of CryoPort in a research note on Monday. Finally, Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Key Stories Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.